drugset
Drugs / Recombinant Human Alkaline Phosphatase
last change Jan 2024 re-read 3 minutes ago

Recombinant Human Alkaline Phosphatase

also known as recAP

Protein / enzyme biologic

Developed for
acute kidney injury
Investigated by
AM-Pharma

Trials 1

today NCT04411472 · Ph 3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT04411472 Nov 2020 → Aug 2022 acute kidney injury AM-Pharma Terminated Mixed
Comparator or background therapy1 trial
Phase 1 NCT04923282 Comparator May → Jul 2021 — AM-Pharma Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2018-03-09 Pfizer AM‐Pharma announces Phase II study results of recAP in sepsis‐associated Acute Kidney Injury pfizer.com ↗
2017-05-22 Pfizer Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (Recap) Phase II Trial In Acute Kidney Injury pfizer.com ↗
2016-05-10 Pfizer AM‐Pharma publishes safety and pharmacokinetic data from Phase I recAP trial pfizer.com ↗
2016-04-26 Pfizer AM‐Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial pfizer.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Recombinant human alkaline phosphatase “Recombinant Human Alkaline Phosphatase (recAP) Administered Intravenously” NCT04923282 ↗
1

NCT04411472 ↗
Known as recAP “Recombinant Human Alkaline Phosphatase (recAP) Administered Intravenously” NCT04923282 ↗
Modality Protein / enzyme biologic “Ilofotase alfa is a human recombinant alkaline phosphatase” PMID 38172296 ↗ Jan 2024
Route Intravenous “Treatment is by 1 hour intravenous infusion, for three days.” NCT04411472 ↗